Key sunitinib‐related biomarkers for renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) contributed to 403,262 new cases worldwide in 2018, which constitutes 2.2% of global cancer, nevertheless, sunitinib, one of the major targeted therapeutic agent for RCC, often developed invalid due to resistance. Emerging evidences suggested sunitinib can impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yun, Dong, Shiqiang, Song, Yuxuan, Hou, Dingkun, Wang, Lili, Li, Bowen, Wang, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Bioinformatics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495283/
https://www.ncbi.nlm.nih.gov/pubmed/34402193
http://dx.doi.org/10.1002/cam4.4206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495283/
https://www.ncbi.nlm.nih.gov/pubmed/34402193
http://dx.doi.org/10.1002/cam4.4206

Ejemplares similares